Immune cell therapy for advanced mesothelioma
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new type of immune cell therapy made from donor cells that are trained to target two specific proteins found on mesothelioma tumors. The goal is to see if these cells can safely shrink tumors or slow the disease when given directly into the chest or belly area.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a confirmed diagnosis of mesothelioma that cannot be removed with surgery, or has come back or spread.
- You must have tried at least one standard treatment, or your doctor has said you cannot or should not take standard therapy.
- Your tumor must have certain proteins (MSLN and FAP) that the new cells are designed to attack.
- You must be in generally good health (able to care for yourself and do light activities).
- You must not have serious infections, uncontrolled heart or lung problems, or other major health issues that would make the treatment risky.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests a treatment that uses a patient’s immune cells (dendritic cell therapy) combined with surgery for epithelioid mesothelioma. It aims to help the immune system better recognize and attack the cancer after chemotherapy and before/around surgery.
This trial tests a new combination of two immunotherapy drugs plus standard chemotherapy and a targeted therapy for people with advanced mesothelioma who have not had treatment before. The goal is to see if this combination can shrink tumors and help people live longer.
This trial tests a new treatment that uses your own immune cells (T cells) engineered to find and attack cancer cells that have a protein called mesothelin on their surface. It is for people with advanced or recurrent esophagogastric cancer (cancer of the esophagus or stomach) or malignant peritoneal mesothelioma (a rare cancer of the lining of the abdomen). The treatment involves collecting your T cells, modifying them in a lab, and then giving them back to you after a short course of chemotherapy to help them work.
This trial tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to standard chemotherapy helps people with malignant mesothelioma live longer and feel better. It's for patients who can't have surgery or radiation, and it may be an option if you haven't had treatment before or have had limited prior treatment.
This trial tests a new type of cell therapy (CAR-T cells) that is designed to find and attack cancer cells showing a protein called mesothelin. It may be an option for people with advanced solid tumors who have exhausted standard treatments.
This trial tests a therapy using your own immune cells (T cells) modified to target mesothelin (MSLN), a protein found on some cancer cells. It may help people with certain advanced solid tumors that have not responded to or can't tolerate standard treatments.
Hear when a new Malignant Pleural Mesotheliomas trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.